Clinical trials: Head and Neck Cancers- Squamous Cell
Head and Neck Cancer Squamous Cell Carcinoma, ELDERLY PEOPLE
Hypofractionated Radiotherapy for HNSCC in Elderly Patients
Head and neck squamous cell carcinoma (HNSCC) is a common malignant tumor, with 25% of HNSCC patients diagnosed at over 70 years of age. As the population ages, it is expected that by 2030, this proportion will exceed 60%.
- Conditions
- Head and Neck Cancer Squamous Cell Carcinoma, ELDERLY PEOPLE, Hypofractionation
- Trial name
- HNSCC (NCT06768125)
- Testing
- Hypofractionated Radiation Therapy
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Head and Neck Cancer, Carcinoma, Squamous Cell
Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer
Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)
- Conditions
- Head and Neck Cancer, Carcinoma, Squamous Cell, Neoplasms, Oral, Neoplasms, Pharyngeal
- Trial name
- INFIELD (NCT03067610)
- Testing
- Intensity Modulated Radiation Therapy, chemotherapy
- Where
- 2 sites in United States
- Volunteers
- 72 people
- Sponsor
- University of Texas Southwestern Medical Center
HPV16+ Squamous Cell Carcinoma
A Study of HB-202/HB-201 in People With Human Papilloma Virus 16-Positive Head and Neck Squamous Cell Cancer (HPV 16+ HNSCC)
The researchers are doing this study to find out if HB-202/HB-201 is a feasible treatment for people with HPV 16-positive head and neck squamous cell cancer (HPV 16+ HNSCC) who have received standard treatment for their disease…
- Trial name
- NCT06373380
- Testing
- HB-200
- Where
- 7 sites in United States
- Volunteers
- 7 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer, Head and Neck Cancer
Immunoreactivity to Cetuximab in Cancer Patients
RATIONALE: Studying samples of blood in the laboratory may help doctors predict which patients will develop hypersensitivity to cetuximab.
- Trial name
- NCT00896896
- Testing
- immunologic technique, laboratory biomarker analysis
- Volunteers
- 538 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
Study of NKTR 255 in Combination With Cetuximab in Solid Tumors
This is a Phase 1b/2, open-label multicenter study evaluating NKTR-255 as a monotherapy and together with cetuximab in patients with head and neck squamous cell carcinoma (HNSCC) and colorectal carcinoma (CRC).
- Trial name
- NCT04616196
- Testing
- NKTR-255, Cetuximab
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- Nektar Therapeutics
Esophageal Squamous Cell Carcinoma
Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer
Esophageal squamous cell cancer (ESCC) has a high incidence in China. Although the fast development of immune check point inhibitors (ICIs), the rate of pCR is limited with the mode of ICIs combined with neoadjuvant…
- Trial name
- NCT07016724
- Testing
- cadonilizumab combined with neoadjuvant radiochemotherapy, neoadjuvant radiochemotherapy
- Where
- China
- Volunteers
- 208 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Head and Neck Cancer
4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)
The primary objective of this study is to estimate the modulation of intermediate biological endpoints of the combination of 4-HPR and SCH66336, a farnesyl transferase inhibitor (FTI), across 4 randomly assigned dose levels in…
- Trial name
- NCT00102635
- Testing
- Fenretinide (4-HPR), SCH66336
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Neoplasms, Carcinoma, Squamous Cell
BIBW 2992 (Afatinib) in Head & Neck Cancer
The primary objective of this study is to explore the efficacy of BIBW 2992 compared with cetuximab (Erbitux) in patients with metastatic or recurrent head and neck cancer after failure of platinum-containing therapy.
- Trial name
- NCT00514943
- Testing
- BIBW 2992, Cetuximab
- Where
- 36 sites in United States, Belgium and 2 more
- Volunteers
- 124 people
- Sponsor
- Boehringer Ingelheim
Head and Neck Cancer
Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002659
- Testing
- cisplatin-e therapeutic implant
- Where
- 28 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Matrix Pharmaceutical
Head and Neck Cancer
Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00639769
- Testing
- cisplatin, irinotecan hydrochloride
- Where
- 8 sites in United States
- Volunteers
- 41 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- NEXUS-01 (NCT06465069)
- Testing
- LY4052031, Pembrolizumab
- Where
- 39 sites in United States, Australia and 6 more
- Volunteers
- 460 people
- Sponsor
- Eli Lilly and Company
Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck
Deep sequencIng in Cutaneous Squamous CEll caRciNomas
To comprehensively describe the molecular profile of the tumour ecosystem of cutaneous squamous cell carcinoma (CSCC) patients treated with neoadjuvant immunotherapy using single-cell sequencing and bulk genomic profiling.
- Conditions
- Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck, Neoplasms, Non-melanoma Skin Cancer
- Trial name
- DISCERN (NCT05878288)
- Testing
- Cemiplimab
- Where
- Australia
- Volunteers
- 11 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Carcinoma, Squamous Cell of Head and Neck, Squamous Cell Carcinoma of the Head and Neck
Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma
The Epidermal Growth Factor Receptor (EGFR) is highly expressed in SCCHN and its overexpression is associated with poor patient outcome. EGFR is a promising target of anticancer therapy.
- Conditions
- Carcinoma, Squamous Cell of Head and Neck, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head And Neck
- Trial name
- NCT00903461
- Testing
- EGFR Antisense DNA
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Pittsburgh
SCC - Squamous Cell Carcinoma, Upper Aero-digestive Tract (UADT) Neoplasm
Prognostic Value of Measuring CtDNA in a Cohort of Patients With Stage III and IV Upper Aero-digestive Tract (UADT) Cancer , Treated With Curative RADiOtherapy With or Without Concomitant Treatment.
Squamous cell carcinomas of the upper aero-digestive tract (SCC-UADT) represent the seventh cause of cancer and affect approximately 600,000 patients per year worldwide.
- Trial name
- CIRADOR (NCT06479070)
- Testing
- Blood samples
- Where
- 7 sites in France, Switzerland
- Volunteers
- 188 people
- Sponsor
- Institut de Cancérologie de Lorraine
OPMD, Oral Cancer , Oral Squamous Cell Carcinoma, Oral Cavity Cancer
The Importance of Mucosal Screening in the Prevention of Oral Cancer.
Patients attending the Department of Oral Mucosal and Periodontal Diseases at the University Dental Center of the Medical University of Warsaw who provide written informed consent will be invited to participate in the study.
- Conditions
- OPMD, Oral Cancer , Oral Squamous Cell Carcinoma, Oral Cavity Cancer, Oral Potentially Malignant Lesions, Leukoplakia Oral
- Trial name
- NCT07682883
- Testing
- Fluorescent oral examination (FOE), Conventional oral examination
- Where
- Poland
- Volunteers
- 1,383 people, healthy volunteers welcome
- Sponsor
- Medical University of Warsaw
Head and Neck Cancer
DNA Analysis of Tumor Tissue Samples From Patients With Human Papilloma Virus-Associated Cancer of the Oropharynx
RATIONALE: Studying samples of tumor tissue in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897988
- Testing
- gene expression analysis, mutation analysis, polyacrylamide gel electrophoresis
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Vanderbilt University Medical Center
Nasopharyngeal Neoplasms, Carcinoma, Squamous Cell
Benefit of Adding Chemotherapy And/Or Modification of Radiotherapy Schedule for Advance Nasopharyngeal Carcinoma (T3-4N0-1M0)
To test the therapeutic ratio of accelerated radiotherapy and/or chemotherapy on locally advanced nasopharyngeal carcinoma.
- Trial name
- NCT00563862
- Testing
- Conventional RT, Accelerated RT, Cisplatin
- Where
- 5 sites in China
- Volunteers
- 465 people
- Sponsor
- Hospital Authority, Hong Kong
HPV-positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)
The purpose of this study is to assess risk for HPV driven oropharyngeal cancers by using HPV blood tests and clinical features (such as tumor stage and smoking status) to determine appropriate treatment to improve survival…
- Trial name
- NCT07513324
- Testing
- Pembroluzimab, Observation
- Sponsor
- Dana-Farber Cancer Institute
Carcinoma, Squamous Cell of Head and Neck
Treatment of Advanced Head and Neck Cancer
This study will investigate the efficacy of opioid growth factor (OGF) on tumor size and survival in patients with head and neck cancer who have failed standard therapy.
- Trial name
- NCT00982696
- Testing
- Opioid Growth Factor
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Milton S. Hershey Medical Center
Locally Advanced Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy
Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC
Head and Neck Squamous Cell Carcinoma (HNSCC) is the most common malignant tumor of the head and neck, accounting for 90% of head and neck malignancies, and 16% to 40% of systemic malignancies.
- Trial name
- NCT04947241
- Testing
- PD-1 inhibitor+ Gemcitabine + Cisplatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.